137 related articles for article (PubMed ID: 16520485)
21. Smoking is not associated with nonalcoholic fatty liver disease.
Chavez-Tapia NC; Lizardi-Cervera J; Perez-Bautista O; Ramos-Ostos MH; Uribe M
World J Gastroenterol; 2006 Aug; 12(32):5196-200. PubMed ID: 16937532
[TBL] [Abstract][Full Text] [Related]
22. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis.
Charlton M
Curr Opin Organ Transplant; 2013 Jun; 18(3):251-8. PubMed ID: 23652610
[TBL] [Abstract][Full Text] [Related]
23. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome.
Mattar SG; Velcu LM; Rabinovitz M; Demetris AJ; Krasinskas AM; Barinas-Mitchell E; Eid GM; Ramanathan R; Taylor DS; Schauer PR
Ann Surg; 2005 Oct; 242(4):610-7; discussion 618-20. PubMed ID: 16192822
[TBL] [Abstract][Full Text] [Related]
24. Impact of fatty liver disease and metabolic syndrome on incident type 2 diabetes; a population based cohort study.
Mitsuhashi K; Hashimoto Y; Hamaguchi M; Obora A; Kojima T; Fukuda T; Fukui M
Endocr J; 2017 Nov; 64(11):1105-1114. PubMed ID: 28867686
[TBL] [Abstract][Full Text] [Related]
25. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.
Baranova A; Tran TP; Birerdinc A; Younossi ZM
Aliment Pharmacol Ther; 2011 Apr; 33(7):801-14. PubMed ID: 21251033
[TBL] [Abstract][Full Text] [Related]
26. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study.
Petta S; Eslam M; Valenti L; Bugianesi E; Barbara M; Cammà C; Porzio M; Rosso C; Fargion S; George J; Craxì A
Liver Int; 2017 Sep; 37(9):1389-1396. PubMed ID: 28235154
[TBL] [Abstract][Full Text] [Related]
27. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them.
Hui JM; Farrell GC
J Gastroenterol Hepatol; 2003 Oct; 18(10):1115-7. PubMed ID: 12974896
[No Abstract] [Full Text] [Related]
28. Nonalcoholic fatty liver disease: are you at risk?
Johns Hopkins Med Lett Health After 50; 2013 Jun; 25(4):3. PubMed ID: 27024624
[No Abstract] [Full Text] [Related]
29. Nonalcoholic fatty liver disease and the metabolic syndrome.
Marchesini G; Babini M
Minerva Cardioangiol; 2006 Apr; 54(2):229-39. PubMed ID: 16778754
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease.
Sanyal AJ
Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):46-53. PubMed ID: 16265100
[TBL] [Abstract][Full Text] [Related]
31. Nonalcoholic fatty liver disease as a feature of the metabolic syndrome.
Socha P; Wierzbicka A; Neuhoff-Murawska J; Włodarek D; Podleśny J; Socha J
Rocz Panstw Zakl Hig; 2007; 58(1):129-37. PubMed ID: 17711101
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of metabolic syndrome and nonalcoholic steatohepatitis.
Sertoglu E; Uyanik M; Kayadibi H
J Clin Gastroenterol; 2015 Apr; 49(4):352-3. PubMed ID: 25551207
[No Abstract] [Full Text] [Related]
33. Nonalcoholic fatty liver disease as a complication of insulin resistance.
Abdelmalek MF; Diehl AM
Med Clin North Am; 2007 Nov; 91(6):1125-49, ix. PubMed ID: 17964913
[TBL] [Abstract][Full Text] [Related]
34. Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease.
Oni ET; Sinha P; Karim A; Martin SS; Blaha MJ; Agatston AS; Blumenthal RS; Meneghelo RS; Conceiçao RD; Santos RD; Nasir K
Arch Med Res; 2014 Jan; 45(1):52-7. PubMed ID: 24333254
[TBL] [Abstract][Full Text] [Related]
35. The Fatty Liver Index: A Simple and Accurate Predictor of Colorectal Adenoma in an Average-Risk Population.
Ze EY; Kim BJ; Jun DH; Kim JG; Kang H; Lee DY
Dis Colon Rectum; 2018 Jan; 61(1):36-42. PubMed ID: 29219920
[TBL] [Abstract][Full Text] [Related]
36. Metabolic Syndrome: One Speckled Stone Kills a Flock of Birds?
Bonde Y; Angelin B
Trends Mol Med; 2017 Feb; 23(2):97-99. PubMed ID: 28082126
[TBL] [Abstract][Full Text] [Related]
37. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.
Hamaguchi M; Kojima T; Takeda N; Nagata C; Takeda J; Sarui H; Kawahito Y; Yoshida N; Suetsugu A; Kato T; Okuda J; Ida K; Yoshikawa T
World J Gastroenterol; 2007 Mar; 13(10):1579-84. PubMed ID: 17461452
[TBL] [Abstract][Full Text] [Related]
38. Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease.
Shetty A; Hsu JW; Manka PP; Syn WK
Dig Dis Sci; 2018 Dec; 63(12):3187-3206. PubMed ID: 30121811
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C infection and nonalcoholic fatty liver disease.
Cheung O; Sanyal AJ
Clin Liver Dis; 2008 Aug; 12(3):573-85, viii-ix. PubMed ID: 18625429
[TBL] [Abstract][Full Text] [Related]
40. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease.
Dumas ME; Kinross J; Nicholson JK
Gastroenterology; 2014 Jan; 146(1):46-62. PubMed ID: 24211299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
